These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 19432937)

  • 21. Analysis of safety, risk factors and pretreatment methods during rush hymenoptera venom immunotherapy.
    Gorska L; Chelminska M; Kuziemski K; Skrzypski M; Niedoszytko M; Damps-Konstanska I; Szymanowska A; Siemińska A; Wajda B; Drozdowska A; Jutel M; Jassem E
    Int Arch Allergy Immunol; 2008; 147(3):241-5. PubMed ID: 18594155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous manifestations in Hymenoptera and Diptera anaphylaxis: relationship with basal serum tryptase.
    Potier A; Lavigne C; Chappard D; Verret JL; Chevailler A; Nicolie B; Drouet M
    Clin Exp Allergy; 2009 May; 39(5):717-25. PubMed ID: 19302252
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Venom immunotherapy: tolerance to a 3-day protocol of rush-immunotherapy.
    Díez Gómez ML; Quirce Gancedo S; Juliá de Páramo B
    Allergol Immunopathol (Madr); 1995; 23(6):277-84. PubMed ID: 8579006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunotherapy against hymenoptera venom: report of ten patients].
    Guzmán M MA; Salinas L J; Toche P P; Marinovic M MA; Gallardo O AM
    Rev Med Chil; 2007 Dec; 135(12):1566-71. PubMed ID: 18357358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic and local reactions of bee venom immunotherapy in Iran.
    Bemanian MH; Farhoudi A; Pourpak Z; Gharagozlou M; Movahedi M; Nabavi M; Mozafari H; Mohammadzadeh I; Chavoshzadeh Z; Shirkhoda Z
    Iran J Allergy Asthma Immunol; 2007 Dec; 6(4):203-6. PubMed ID: 18094443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of idiopathic anaphylaxis in an adolescent.
    Pitt TJ; Cisneros N; Kalicinsky C; Becker AB
    J Allergy Clin Immunol; 2010 Aug; 126(2):415-6; author reply 416. PubMed ID: 20624653
    [No Abstract]   [Full Text] [Related]  

  • 27. [Insect venom allergy].
    Müller UR
    Ther Umsch; 1994 Jan; 51(1):38-44. PubMed ID: 7511840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The recent article on 'Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy' by Niedoszytko et al.
    Kontou-Fili K
    Allergy; 2009 Nov; 64(11):1685. PubMed ID: 19824888
    [No Abstract]   [Full Text] [Related]  

  • 29. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis.
    Cox L; Platts-Mills TA; Finegold I; Schwartz LB; Simons FE; Wallace DV; ;
    J Allergy Clin Immunol; 2007 Dec; 120(6):1373-7. PubMed ID: 17996286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical and biological surveillance after the cessation of Hymenoptera venom desensitization].
    Touraine F; Talayrach D; Florea O; Brianchon Ch; Preux PM; Bonnaud F
    Eur Ann Allergy Clin Immunol; 2003 Nov; 35(9):335-9. PubMed ID: 14716961
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcome survey of insect venom allergic patients with venom immunotherapy in a rural population.
    Roesch A; Boerzsoenyi J; Babilas P; Landthaler M; Szeimies RM
    J Dtsch Dermatol Ges; 2008 Apr; 6(4):292-7. PubMed ID: 18042250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance venom immunotherapy administered at 3-month intervals is both safe and efficacious.
    Goldberg A; Confino-Cohen R
    J Allergy Clin Immunol; 2001 May; 107(5):902-6. PubMed ID: 11344360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.
    Casale TB; Busse WW; Kline JN; Ballas ZK; Moss MH; Townley RG; Mokhtarani M; Seyfert-Margolis V; Asare A; Bateman K; Deniz Y;
    J Allergy Clin Immunol; 2006 Jan; 117(1):134-40. PubMed ID: 16387596
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mastocytosis and allergy.
    Greenhawt M; Akin C
    Curr Opin Allergy Clin Immunol; 2007 Oct; 7(5):387-92. PubMed ID: 17873577
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Specific immunotherapy in honeybee venom allergy: a comparative study using aqueous and aluminium hydroxide adsorbed preparations.
    Ruëff F; Wolf H; Schnitker J; Ring J; Przybilla B
    Allergy; 2004 Jun; 59(6):589-95. PubMed ID: 15147443
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Bee venom immunotherapy: whom to treat with which regiment for how long?].
    Díez Gómez AM
    Allergol Immunopathol (Madr); 1995; 23(6):256-62. PubMed ID: 8579002
    [No Abstract]   [Full Text] [Related]  

  • 37. [Hyposensitization to insect venom allergy: small animals--big effect].
    Reiser-Perić P; Schiller S
    Pflege Z; 2002 Jul; 55(7):480-4. PubMed ID: 12192781
    [No Abstract]   [Full Text] [Related]  

  • 38. [Allergy to bee and yellow jacket venoms].
    Saari S; Kalimo K; Viander M; Henriksson S
    Duodecim; 1985; 101(4):393-401. PubMed ID: 3979324
    [No Abstract]   [Full Text] [Related]  

  • 39. Hymenoptera sting anaphylaxis: detection and clinical significance of individual bee and wasp venoms specific IgE and IgG4 antibodies.
    Ameno S; Ameno K; Fuke C; Shinohara T; Kiriu T; Kinoshita H; Ijiri I
    Nihon Hoigaku Zasshi; 1993 Jun; 47(3):207-12. PubMed ID: 8345683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD28 expression is increased in venom allergic patients but is not modified by specific immunotherapy.
    Tsicopoulos A; Labalette M; Akoum H; Duez C; Wallaert B; Dessaint JP; Tonnel AB
    Clin Exp Allergy; 1996 Oct; 26(10):1119-24. PubMed ID: 8911696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.